Combinatorial chemoprevention of intestinal neoplasia

Christopher J. Torrance, Peta E. Jackson, Elizabeth Montgomery, Kenneth W. Kinzler, Bert Vogelstein, Allan Wissner, Maria Nunes, Philip Frost, Carolyn M. Discafani

Research output: Contribution to journalArticle

Abstract

A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APC(Min/+) mice developed ~20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.

Original languageEnglish (US)
Pages (from-to)1024-1028
Number of pages5
JournalNature medicine
Volume6
Issue number9
DOIs
StatePublished - Sep 1 2000

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B., Wissner, A., Nunes, M., Frost, P., & Discafani, C. M. (2000). Combinatorial chemoprevention of intestinal neoplasia. Nature medicine, 6(9), 1024-1028. https://doi.org/10.1038/79534